[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022003507A - Binding modules comprising modified ehd2 domains. - Google Patents

Binding modules comprising modified ehd2 domains.

Info

Publication number
MX2022003507A
MX2022003507A MX2022003507A MX2022003507A MX2022003507A MX 2022003507 A MX2022003507 A MX 2022003507A MX 2022003507 A MX2022003507 A MX 2022003507A MX 2022003507 A MX2022003507 A MX 2022003507A MX 2022003507 A MX2022003507 A MX 2022003507A
Authority
MX
Mexico
Prior art keywords
modified
binding molecules
binding modules
ehd2
ehd2 domains
Prior art date
Application number
MX2022003507A
Other languages
Spanish (es)
Inventor
Roland Kontermann
Oliver Seifert
Original Assignee
Univ Stuttgart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Stuttgart filed Critical Univ Stuttgart
Publication of MX2022003507A publication Critical patent/MX2022003507A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to binding molecules comprising two polypeptide chains, wherein the peptide chains comprise modified EHD2 domains allowing heterodimerization only, thereby preventing homodimers, nucleic acids encoding such binding molecules and uses of such binding molecules or nucleic acids encoding such binding molecules in therapy.
MX2022003507A 2019-09-25 2020-09-25 Binding modules comprising modified ehd2 domains. MX2022003507A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19199639 2019-09-25
PCT/EP2020/077008 WO2021058804A1 (en) 2019-09-25 2020-09-25 Binding modules comprising modified ehd2 domains

Publications (1)

Publication Number Publication Date
MX2022003507A true MX2022003507A (en) 2022-04-25

Family

ID=68109107

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003507A MX2022003507A (en) 2019-09-25 2020-09-25 Binding modules comprising modified ehd2 domains.

Country Status (9)

Country Link
US (1) US20220372147A1 (en)
EP (1) EP4034244A1 (en)
JP (1) JP2022550316A (en)
KR (1) KR20220071210A (en)
CN (1) CN115066275A (en)
AU (1) AU2020356407A1 (en)
CA (1) CA3155725A1 (en)
MX (1) MX2022003507A (en)
WO (1) WO2021058804A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4454706A1 (en) 2023-04-24 2024-10-30 Universität Stuttgart Novel egfr binding proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20110217302A1 (en) * 2008-10-10 2011-09-08 Emergent Product Development Seattle, Llc TCR Complex Immunotherapeutics
JP5851419B2 (en) * 2009-12-29 2016-02-03 エマージェント プロダクト デベロップメント シアトル， エルエルシー Heterodimer binding proteins and uses thereof
WO2013075027A2 (en) * 2011-11-17 2013-05-23 Emergent Product Development Seattle, Llc Anti-sil6xr complex binding domains and methods of use
US20180194861A1 (en) 2015-07-10 2018-07-12 Abbvie Inc. IgM- or IgE-Modified Binding Proteins and Uses Thereof

Also Published As

Publication number Publication date
KR20220071210A (en) 2022-05-31
AU2020356407A1 (en) 2022-04-07
WO2021058804A1 (en) 2021-04-01
JP2022550316A (en) 2022-12-01
EP4034244A1 (en) 2022-08-03
CA3155725A1 (en) 2021-04-01
CN115066275A (en) 2022-09-16
US20220372147A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
MX2023003630A (en) Improved serum albumin binding immunoglobulin single variable domains.
MX2024008521A (en) Improved serum albumin binders.
MX2019008496A (en) Improved serum albumin binders.
PH12019500596A1 (en) Recombinant binding proteins and their use
PH12018501025A1 (en) Improved tnf binders
MX2018010824A (en) Inducible binding proteins and methods of use.
BR112017019862A2 (en) tumor immunity modulation through protein-mediated O 2 release
WO2017085172A3 (en) Improved serum albumin binders
PH12019500609A1 (en) Cd123 binding proteins and related compositions and methods
MX366588B (en) Modified j-chain.
MX2024003743A (en) Aggrecan binding immunoglobulins.
BR112017019625A2 (en) udp-glycosyltransferases
MX2021000155A (en) Multifunctional protein molecules comprising decorin and use thereof.
NZ745999A (en) Anti-tnfalpha-antibodies and functional fragments thereof
EA202190240A1 (en) RECOMBINANT PROTEIN OPTIONS
WO2015166105A3 (en) Ion channel modulators and uses thereof
MX2016006277A (en) Modified kz144 endolysin sequence.
MX2019014400A (en) Adamts binding immunoglobulins.
MX2022003507A (en) Binding modules comprising modified ehd2 domains.
MX2024002182A (en) Tgf-beta-rii binding proteins.
MX2021015766A (en) Novel cancer antigens and methods.
EP4257193A3 (en) Trispecific and/or trivalent binding proteins
MX2022000725A (en) Factor h potentiating antibodies and uses thereof.
MX2021011854A (en) Anticancer combination therapy.
BR112022001695A2 (en) T-CELL RECEPTORS AND METHODS OF USING THEM